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CONCLUSION: HRT is the most cost-effective option, followed
by bisphosphonates, for 50-year-old hypothetical females, but
some assumptions and limitations apply (including small sample
sizes for the calcitonin and raloxifene groups, and a likely selec-
tion bias in that bisphosphonate users are more likely to report
longer duration of glucocorticoid therapy). Because few guide-
lines included cost-effectiveness information, consideration of
these results may facilitate better management of glucocorticoid-
induced osteoporosis.
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OBJECTIVE: Abatacept is a new selective co-stimulation modu-
lator recently approved in Brazil for the treatment of patients
with moderately to severely active rheumatoid arthritis (RA) and
inadequate response to one or more disease-modifying anti-
rheumatic drugs (DMARDs). We estimated the cost-effectiveness
of Abatacept in patients with inadequate response to Methotr-
exate. METHODS: We developed a Markov simulation model to
depict progression of functional disability over time in patients
with moderately to severely active RA and inadequate response
to MTX. Functional disability was expressed in terms of the
Health Assessment Questionnaire Disability Index (HAQ-DI).
Patients were assumed to receive weekly pulse MTX alone or
weekly pulse MTX plus abatacept administered on days 1, 14,
and 29, and every 4 weeks thereafter. Costs with drug acquisi-
tion, administration and monitoring were considered. Estima-
tions used data from a Phase III clinical trial of abatacept in
patients with inadequate response to MTX (AIM) plus secondary
data sources. Cost-effectiveness of abatacept was expressed in
terms of the incremental cost (2006 Brazil R$) per quality-
adjusted life-year (QALY) gained versus MTX therapy alone;
lifetime horizons was employed in the analyses. Costs and health
effects were discounted at 3% annually. RESULTS: Over the
lifetime, abatacept therapy was estimated to yield an average of
1.61 additional QALYs per patient (vs. MTX alone) at a mean
incremental cost of R$146.095/QALY (US$83,483, US$1 =
R$1.75). CONCLUSION: Abatacept presented the best cost-
effectiveness ratio vis-à-vis etanercept, adalimumab, and
inﬂiximab, with its incremental costs of R$202.581/QALY,
R$189.100/QALY and R$236.479/QALY, respectively vs. Meth-
rotexate alone.
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OBJECTIVE: Rituximab is a monoclonal antibody with demon-
strated efﬁcacy (REFLEX trial) in rheumatoid arthritis patients
who responded inadequately to anti-TNF drugs (Cohen et al.
2006). The study assessed the total cost of rituximab therapy in
comparison with inﬂiximab, adalimumab, etanercept and abata-
cept under a private payer perspective in Brazil. A budget impact
analysis was performed. METHODS: This study assumed the
same efﬁcacy for all drugs, since there has not been any head-
to-head trial available until now, although indirect comparisons
show higher ACR response rates for rituximab. Direct annual
medical costs for biological drugs, IV administration, weekly
metotrexate (MTX) and routine exams were taken from a panel
of Brazilian rheumatologists. Base case dosages considered were:
rituximab (2 g every 8 months), abatacept (750 mg at weeks 0, 2,
4 and then every 4 weeks), inﬂiximab (4 mg/kg at weeks 0, 2, 6
and every 8 weeks), adalimumab (40 mg every other week) and
etanercept (50 mg every week). Local administration costs were
obtained from Scheinberg et al. 2005. Costs were reported in
2007 Brazilian Reais and discounted at a 5% rate in the BIA.
Therapies were evaluated using a 5-year horizon. In order to
assess uncertainty, one and two-way sensitivity analyses were
performed. RESULTS: In the base case scenario, rituximab
therapy resulted in a total annual cost of R$46,388 per patient.
Total annual costs per patient for the comparators were:
R$79,394 for inﬂiximab, R$90,831 for adalimumab, R$120,351
for etanercept and R$77,118 for abatacept. In the BIA, ritux-
imab therapy resulted in total savings of R$94,201,413 in 5 years
considering the population in the private health care system only.
Results were sensitive to dosage schedule (rituximab, inﬂiximab
and abatacept) and drug costs. CONCLUSION: Results of this
study suggest that therapy with rituximab is a dominant alterna-
tive for patients with rheumatoid arthritis in the Brazilian private
health care system.
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OBJECTIVE: To assess the direct and indirect economic conse-
quences of rheumatoid arthritis (RA) using real-world data.
METHODS: Medical Expenditure Panel Survey (MEPS) 2004
data was used to identify non-institutionalized U.S. persons with
RA. MEPS is a comprehensive survey of approximately 35,000
individuals consisting of detailed health care resource use expen-
ditures by payer, employment and income, insurance detail and
quality of life (QoL) information. These data are novel because
they are nationally representative, capture the elderly and their
expenditure better than managed care databases, and contain
direct and indirect costs and QoL measures in the same popula-
tion. Multiple linear and semi-log regressions were applied to
estimate the total annual health care expenditure and income
loss associated with RA. Covariates in expenditure equations
included demography, comorbidities and overall health status.
Semi-log regression for income rendered the distribution of
income symmetric. Covariates in the income equations included
demography, comorbidities, education, occupation and health
status. RESULTS: A total of 136 patients with RA were identiﬁed
in the data; 76% were women, and 56% were 41–64 years of
age. Total annual incremental expenditure associated with RA
was $4422 (P < 0.01) with adjusted R2 of 0.16 in the linear
regression and 0.41 in the semi-log regression. 14% of those
expenses were paid by the individual or their family, 28% by
Medicare, 39% by private insurance and 14% by Medicaid. As
expected, deterioration in overall health status increased health
care expenditures monotonically. In the income equation
(adjusted R2 = 0.39), persons with RA earned $3526 less annu-
ally (P = 0.03) than the mean income of $26,594 consistent with
the US Census Bureau, translating into a 13% decrease. Income
increased with education and with improved overall health
status. CONCLUSION: Even when controlling for other factors,
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the economic impact of rheumatoid arthritis alone is substantial
with the indirect productivity or income loss as large as the
health care costs.
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DISEASE SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS OF
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OBJECTIVE: To assess the relationship between economic
burden and physical functioning or disease severity in rheu-
matoid arthritis (RA). METHODS: Medline, Embase, BIOSIS,
Derwent Drug File, the Cochrane library and NHS-EED were
searched on 12th March 2007 for cost-of-illness (COI) and cost-
effectiveness studies in RA. RESULTS: A total of 909 unique
citations were retrieved. Nine studies presented COI results; with
seven studies presenting data on the relationship between direct
and indirect costs and physical functioning or disease severity.
The Health Assessment Questionnaire (HAQ) was used in three
studies to assess functional ability. Higher HAQ scores at base-
line were found to be signiﬁcant predictors of higher future direct
costs in two studies. A third study used both HAQ and the
Hannover Functional Status Questionnaire (FFbH) to assess
functional ability. For patients with an HAQ score <1.2 (or
>70% of full FFbH function) the mean annual direct costs were
€3225 and indirect costs were €8,811; for patients with an HAQ
score between 1.2 and 1.7 (FFbH function of 50 to 70%) mean
annual direct costs were €5,661 and indirect costs were €21,580;
whilst for patients with an HAQ score higher than 1.7 (FFbH
functional status of <50% of normal) mean annual direct costs
were €8,403 and indirect costs were €34,915. A further two
studies using the FFbH conﬁrmed these ﬁndings of increased
costs with decreasing functional ability. Finally, in two studies
assessing the relationship between disease severity and costs,
there was a statistically signiﬁcant difference (p < 0.001) in both
direct and indirect costs for each level increase in disease severity
(based on ACR functional classes I, II, III and IV) and increases
in costs with increasing disease severity categorised as no disabil-
ity, mild, moderate and severe. CONCLUSION: The economic
burden of RA appears highly dependent on both the level of
functional disability and disease severity.
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OBJECTIVE: The study is an assessment of the economic impact
of allopurinol hypersensitivity syndrome (AHS) in a managed
care population. METHODS: Due to absence of a speciﬁc ICD-9
CM code for AHS, an algorithm was developed using results of
a modiﬁed Delphi process to identify an AHS episode, and assess
its economic impact from claims data. Allopurinol users were
identiﬁed as those who had a prescription during January 1,
2000 to June 30, 2006. Presence of an AHS episode was assessed
during the continuous eligibility period after the ﬁrst allopurinol
prescription. The start date of an AHS episode was termed as the
index AHS date, and overall health care costs were computed
during a six month period before and after the index AHS date.
Statistical differences in costs per patient per six month period
pre- and post- AHS were assessed using paired t-tests; differences
in proportion with non-zero costs were assessed using McNe-
mar’s test. All costs are expressed in 2007 US Dollars.
RESULTS: A total of 417 allopurinol users experienced at least
one AHS episode during the period following their index allopu-
rinol prescription compared to 124,546 users who did not. The
average cost per patient in the six month period following the
index AHS date was $8598 higher than the prior 6-month period
($14,338 vs. $5,740, P < 0.001). The cost increase was evident
for both medical ($12,032 vs. $4,242, P < 0.001) and pharmacy
components ($2,306 vs. $1,498, P < 0.001). The large difference
in medical costs was primarily due to large differences in inpa-
tient costs ($7497 vs. $2335, P < 0.001), as a signiﬁcantly higher
proportion had a hospitalization following the AHS episode
compared to the pre-index AHS period (40.3% vs. 16.8%,
P < 0.001). CONCLUSION: This study found AHS to have a
signiﬁcant economic impact contributing to an almost three fold
increase in overall health care costs.
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OBJECTIVE: The purpose of this study was to calculate the
treatment cost of femoral neck fracture and ﬁnancial burden of
the annual fracture cases at 2007 ﬁnancial level from health
insurance point of view. METHODS: The costs of the treatment
of femoral neck fractures are modeled according to the actually
NHIFA (National Health Insurance Fund Administration) reim-
bursed types of care including acute inpatient care, chronic inpa-
tient care, outpatient care, pharmaceuticals and medical devices,
home care (nursing), cost of traveling or transport, and sick pay.
Cases in which patients were healing following primary treat-
ment (without complications) and cases with complications were
examined separately. The ﬁnancial burden was estimated by
using data from international literature and Hungarian studies
(number of fractures, mortality, ratio of further treatment, etc.)
which were extrapolated for the average health insurance
treatment cost of one patient. Yearly average in 2007:
USD$1 = 183,83 HUF. RESULTS: The cost of patients in active
age-groups cured by primary treatment can vary in a range of
USD$5093–USD$7549 depending on cost level of individual
care and utilization. The cost of patients with complication
(primary treatment and complication) in active age-groups can
reach USD$9317–USD$16049, depending on cost level of indi-
vidual care and utilization. According to our model calculations,
the cost of primary treatment of femoral neck fractures
and essential further treatment represents an annual burden
of USD$22,676,518–USD$32,194,335 for the health insurance
system. CONCLUSION: In order to reduce the incidence of neck
fractures, one should emphasize the importance of current and
future interventions, which projects the possibility of reducing
the ﬁnancial burden at societal level. The real decrease of ﬁnan-
cial burden can be realized by reducing the risk increasing effect
of risk factors of the whole primary treatment on further treat-
ments, following the implementation of well-established and
uniform professional decisions.
Abstracts A261
